Oramed Pharmaceuticals Inc.
Company & revenue
About Oramed Pharmaceuticals Inc.
Who they are
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes.
Detailed revenue, brand and relationship research has not yet been completed for ORMP.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
72
Strong
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
47
Weak
Financial Strength
41
Business Quality / Moat
45
Management
80
Growth Quality
27
Risk / Durability
30
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
67
Fully Valued
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
64/100
Building Historical Record
Model Score 64/100 — estimates relative performance potential, distinct from WallStreetScore (company quality).
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
WSS currently rates the company as financially and fundamentally strong.
At today’s price, the WSS valuation framework currently reads as moderate rather than unusually attractive.
The model outlook is currently moderate.
- •Strong overall Company Strength score
- •Asset quality scores strongly
- •Valuation scores attractively
- •Recent buyback activity is present
No material warning is currently being highlighted from the available summary data.
Company-specific research
Questions worth answering for ORMP
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving ORMP's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •How long can ORMP fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is ORMP likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •Is ORMP's valuation discount tied to a temporary concern or to a longer-term business risk?
- •What does the current missing revenue history warning mean for the reliability or interpretation of ORMP's score?
Essential Investment Snapshot
Wall Street Score
72
Opportunity Score
67
Market Cap
$183.8M
P/E Ratio
1.1
EPS
$4.23
52-Week High
$5.47
52-Week Low
$2.09
Beta
1.19
Intrinsic Value
$35.95
Shares Outstanding
42.4M
Total Revenue
$0
Total Debt
$733K
Dividend
No current dividend
Liquidation Value / Share
$7.48
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Weakening momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for ORMP
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Community Sentiment
0 active · 0 total callsNo personal call yet on ORMP.
What the Bulls Say
- +Product opportunity: Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral gluc.
What the Bears Say
- −Negative free cash flow may increase the need for outside financing and dilution.
Bull and bear cases summarize disclosed catalysts, growth opportunities and risks; they are not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
2 historical score records availablePrevious Score
66
Jul 24, 2026
Change
+6.5
points
Current Score
72
Oct 1, 2026
Category Changes
ORMP increased 6.5 points because Valuation improved by 15 points.
Positive Contributors
- + Valuation improved by 15 points
Projected Score
Projected Score
73
Projected Change
+75.0%
Preliminary comparable-period financial changes suggest improvement of approximately 0.8 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
UndervaluedCurrent Price
$4.49
Intrinsic Value
$35.95
Difference
−$31.46
-87.5% vs IV
Margin of Safety
87.5%
Related Companies
BiotechnologyRelated Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial